ZVSA — Zyversa Therapeutics Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Zyversa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 7.49 | 13.8 | 108 | 9.14 | 25.5 |
| Operating Profit | -7.49 | -13.8 | -108 | -9.14 | -25.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.08 | -14.9 | -108 | -9.41 | -25.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.08 | -14.1 | -98.3 | -9.41 | -25 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.08 | -14.1 | -98.3 | -9.41 | -25 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.08 | -24.1 | -106 | -9.41 | -25 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -315 | -917 | -467 | -8.48 | -1.06 |
| Dividends per Share |